Update from Novartis
Our partners at Novartis recently provided the following letter regarding their study of the medication Alpelisib (Vijoice) for the treatment of PROS, called EPIK-P4, in the hopes that the PROS community finds the information helpful and relevant. CSC is sharing…
.CSC Visits University of Washington Variant Effects Program
I recently had the opportunity to meet the Variant Effects Program research team at the University of Washington in Seattle, and WOW! I don’t know that I’ve ever met a group of more passionate, and compassionate researchers. CSC was introduced…
.
CSC Research News – Zebrafish Model Updates
Our research partners in the UK and Europe–Drs Hannah Brunsdon, Ralitsa R Madsen, Robert K. Semple, E. Elizabeth Patton, and more–just had a pre-print published detailing their work with Zebrafish and the PIK3CA gene–a project made possible by seed funding…
.
2025 PROS Community Science Update
from Dr Ralitsa Madsen & Team Dear CLOVES Syndrome Community readers, As we approach the festive season, I am once again excited to share this year’s update with you. Writing this newsletter is always one of my favourite responsibilities of…
.
THE EVOLVING LANDSCAPE OF CHARITABLE DEDUCTIONS
Josh Beauregard is a Corporate Controller, a CPA, and Dad to Maddox (13) and Kiki (10). He’s also a caregiver-member of our CLOVES Community, and was kind enough to write this blog post for us, helping demystify the changes coming to…
.